Fraction-variant beam orientation optimization for non-coplanar IMRT

TL;DR

This paper introduces a group sparsity-based beam orientation optimization method for non-coplanar IMRT that creates fraction-variant treatment plans, improving dose sparing and efficiency over traditional fixed-angle plans.

Contribution

The authors develop a novel FV BOO formulation using group sparsity and the Fast Iterative Shrinkage-Thresholding Algorithm for non-coplanar IMRT, enabling fraction-specific beam selection.

Findings

Reduced OAR doses by an average of 3.3% to 3.7% of prescription dose.

Improved PTV dose homogeneity from 0.95 to 0.98 in prostate case.

Achieved similar dosimetry with fewer beams compared to conventional plans.

Abstract

Conventional beam orientation optimization (BOO) algorithms for IMRT assume that the same set of beam angles is used for all treatment fractions. In this paper we present a BOO formulation based on group sparsity that simultaneously optimizes non-coplanar beam angles for all fractions, yielding a fraction-variant (FV) treatment plan. Beam angles are selected by solving a multi-fraction FMO problem involving 500-700 candidate beams per fraction, with an additional group sparsity term that encourages most candidate beams to be inactive. The optimization problem is solved using the Fast Iterative Shrinkage-Thresholding Algorithm. Our FV BOO algorithm is used to create non-coplanar, five-fraction treatment plans for prostate and lung cases, as well as a non-coplanar 30-fraction plan for a head and neck case. A homogeneous PTV dose coverage is maintained in all fractions. The treatment plans are compared with fraction-invariant plans that use a fixed set of beam angles for all fractions. The FV plans reduced mean and max OAR dose on average by 3.3% and 3.7% of the prescription dose, respectively. Notably, mean OAR dose was reduced by 14.3% of prescription dose (rectum), 11.6% (penile bulb), 10.7% (seminal vesicle), 5.5% (right femur), 3.5% (bladder), 4.0% (normal left lung), 15.5% (cochleas), and 5.2% (chiasm). Max OAR dose was reduced by 14.9% of prescription dose (right femur), 8.2% (penile bulb), 12.7% (prox. bronchus), 4.1% (normal left lung), 15.2% (cochleas), 10.1% (orbits), 9.1% (chiasm), 8.7% (brainstem), and 7.1% (parotids). Meanwhile, PTV homogeneity defined as D95/D5 improved from .95 to .98 (prostate case) and from .94 to .97 (lung case), and remained constant for the head and neck case. Moreover, the FV plans are dosimetrically similar to conventional plans that use twice as many beams per fraction. Thus, FV BOO offers the potential to reduce delivery time for non-coplanar IMRT.